Table A3. Association of revised PAM components with 2-year mortality in the external validation cohort of 401 patients from the Dana Farber Cancer Institute.
| Variable | N (%) | Hazard Ratio (95% CI) | P |
|---|---|---|---|
| Patient age, years | |||
| < 65 | 401 (100%) | 1 | - |
| ≥ 65 | 0 (0%) | NA | - |
|
| |||
| Donor type | Global p<.0001 | ||
| HLA-matched, related | 173 (43%) | 1 | - |
| Unrelated, HLA-matched | 174 (43%) | 1.18 (0.83-1.66) | .36 |
| Unrelated, HLA-mismatched | 26 (6%) | 2.86 (1.69-4.83) | <.0001 |
| Unrelated, cord blood | 23 (6%) | 2.76 (1.48-5.15) | .001 |
| HLA-mismatched, related | 5 (1%) | 2.61 (0.94-7.21) | .06 |
|
| |||
| Disease risk | Global p<.0001 | ||
| Low | 34 (8%) | 1 | - |
| Intermediate | 224 (56%) | 1.97 (0.95-4.09) | .07 |
| High | 125 (31%) | 2.81 (1.34-5.88) | .006 |
| Very High | 18 (4%) | 7.08 (2.89-17.30) | <.0001 |
|
| |||
| FEV1* | 401 | 1.13 (1.01-1.25) | .03 |
|
| |||
| Patient/Donor CMV | Global p=.34 | ||
| -/- | 153 (38%) | 1 | - |
| -/+ | 51 (13%) | 1.31 (0.82-2.09) | .26 |
| +/- | 110 (27%) | 1.08 (0.73-1.61) | .70 |
| +/+ | 87 (22%) | 1.39 (0.94-2.07) | .10 |
Abbreviations: CMV, cytomegalovirus
*
FEV1 modeled as a continuous linear variable. Hazard ratio represents relative change in hazard associated with each decrease in FEV1 by 10%.